AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 24, 2013, Pages 9992-9997

  Penchala, Sravan C ^a   Connelly, Stephen ^b   Wang, Yu ^a   Park, Miki S ^a   Zhao, Lei ^b   Baranczak, Aleksandra ^b   Rappley, Irit ^b   Vogel, Hannes ^c   Liedtke, Michaela ^c   Witteles, Ronald M ^c   Powers, Evan T ^b   Reixach, Natàlia ^b   Chan, William K ^a   Wilson, Ian A ^b   Kelly, Jeffery W ^b   Graef, Isabella A ^c   Alhamadsheh, Mamoun M ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crystal structure; Drug design

Indexed keywords

AG 10; PREALBUMIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CARDIOMYOPATHY; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG POTENCY; FAMILIAL AMYLOID CARDIOMYOPATHY; FAMILIAL AMYLOIDOSIS; GENE MUTATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; RAT;

CRYSTAL STRUCTURE; DRUG DESIGN;

AMYLOID; AMYLOIDOSIS; ANIMALS; AREA UNDER CURVE; BENZOATES; BENZOXAZOLES; CARDIOMYOPATHIES; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PREALBUMIN; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PYRAZOLES; RATS; RATS, WISTAR;

EID: 84878956207     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1300761110     Document Type: Article

References (40)

1. Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426(6968):900-904.
2. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366. (Pubitemid 44118036)
3. Johnson SM, et al. (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc Chem Res 38(12):911-921.
4. Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Engl J Med 337(13):898-909. (Pubitemid 27408573)
5. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE (2003) Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 10(3):160-184. (Pubitemid 37372400)
6. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C (1978) Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 121(3):339-356. (Pubitemid 8361803)
7. Monaco HL, Rizzi M, Coda A (1995) Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science 268(5213):1039-1041.
8. Foss TR, Wiseman RL, Kelly JW (2005) The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 44(47):15525-15533. (Pubitemid 41706136)
9. Purkey HE, Dorrell MI, Kelly JW (2001) Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA 98(10):5566-5571. (Pubitemid 32435682)
10. Hammarström P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299(5607):713-716. (Pubitemid 36159487)
11. Sekijima Y, et al. (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121(1):73-85.
12. Ando Y, Suhr OB (1998) Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 5(4):288-300. (Pubitemid 128690769)
13. Benson MD (1989) Familial amyloidotic polyneuropathy. Trends Neurosci 12(3):88-92.
14. Connors LH, et al. (2009) Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 158(4):607-614.
15. Buxbaum J, et al. (2010) Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 159(5):864-870.
16. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99(suppl 4):16427-16432. (Pubitemid 35470989)
17. Jiang X, Buxbaum JN, Kelly JW (2001) The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 98(26):14943-14948. (Pubitemid 34013949)
18. Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10):1286-1300.
19. Falk RH (2011) Cardiac amyloidosis: A treatable disease, often overlooked. Circulation 124(9):1079-1085.
20. Westermark P, Sletten K, Johansson B, Cornwell GG, 3rd (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87(7):2843-2845.
21. Rapezzi C, et al. (2010) Transthyretin-related amyloidoses and the heart: A clinical overview. Nat Rev Cardiol 7(7):398-408.
22. Hammarström P, Schneider F, Kelly JW (2001) Trans-suppression of misfolding in an amyloid disease. Science 293(5539):2459-2462. (Pubitemid 32917328)
23. Alhamadsheh MM, et al. (2011) Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med 3(97):97ra81.
24. Bulawa CE, et al. (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109(24):9629-9634.
25. Coelho T, et al. (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 79(8):785-792.
26. Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13(4):236-249. (Pubitemid 44764463)
27. Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Arch Intern Med 160(6):777-784. (Pubitemid 30165238)
28. Wallace JL (2001) Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15(5):691-703.
29. Jonsén E, Suhr OB, Tashima K, Athlin E (2001) Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life. Amyloid 8(1):52-57. (Pubitemid 32210180)
30. Hamour IM, et al. (2008) Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant 8(5):1056-1059. (Pubitemid 351537754)
31. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 20(1):54-62.
32. Bourgault S, et al. (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 410(4):707-713.
33. Choi S, Kelly JW (2011) A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorg Med Chem 19(4):1505-1514.
34. Tojo K, Sekijima Y, Kelly JW, Ikeda S (2006) Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 56(4):441-449. (Pubitemid 44755449)
35. European Medicines Agency Committee for Medicinal Products for Human Use (2011) Tafamidis Meglumine (Vyndaqel) assessment report, 22 September 2011. EMA/729083/2011. Procedure No. EMEA/H/C/002294.
36. Dwulet FE, Benson MD (1984) Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci USA 81(3):694-698. (Pubitemid 14199012)
37. Damas AM, Ribeiro S, Lamzin VS, Palha JA, Saraiva MJ (1996) Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant. Acta Crystallogr D Biol Crystallogr 52(Pt 5):966-972. (Pubitemid 27064200)
38. Freire E (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 13(19-20):869-874.
39. Bartels T, Choi JG, Selkoe DJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362):107-110.
40. Connolly ML (1983) Solvent-accessible surfaces of proteins and nucleic acids. Science 221(4612):709-713.